An analog of withaferin a activates the MAPK and glutathione "stress" pathways and inhibits pancreatic cancer cell proliferation

Cancer Investigation

Volumn 29, Issue 10, 2011, Pages 668-675

  Liu, Xiaobing ^a   Qi, Wenqing ^a   Cooke, Laurence S ^a   Kithsiri Wijeratne, E M ^b   Xu, Ya Ming ^b   Marron, Marilyn T ^b   Leslie Gunatilaka, A A ^b   Mahadevan, Daruka ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b School of Natural Resources and the Environment   (United States)

Author keywords

4 Epi withaferin A (2); 427 Diacetyl 4 epi withaferin A (3); Apoptosis; Gene expression profiling; Glutathione pathway; MAPK; Pancreatic cancer; Withaferin A (1)

Indexed keywords

4 EPI WITHAFERIN A; 4,27 DIACETYL 4 EPI WITHAFERIN A; ACTIVATING TRANSCRIPTION FACTOR 3; ALDO KETO REDUCTASE FAMILY 1 MEMBER C2; ALDO KETO REDUCTASE FAMILY 1 MEMBER C3; ANTINEOPLASTIC AGENT; BCL2 RELATED PROTEIN A1; GCLC PROTEIN; GLUTATHIONE DERIVATIVE; GLUTATHIONE PEROXIDASE 2; HEAT SHOCK 70KDA PROTEIN 1A; HEAT SHOCK 70KDA PROTEIN 6; HEAT SHOCK PROTEIN 70; HEME OXYGENASE 1; METALLOTHIONEIN; METALLOTHIONEIN 1X; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OXIDOREDUCTASE; SOLUTE CARRIER FAMILY 7 MEMBER 11; STRESS ACTIVATED PROTEIN KINASE; THIOREDOXIN INTERACTING PROTEIN; UNCLASSIFIED DRUG; WITHAFERIN A;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; GENETIC REGULATION; HUMAN; HUMAN CELL; IC 50; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; UPREGULATION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GLUTATHIONE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; WITHANOLIDES;

EID: 81255203811     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.626478     Document Type: Article

References (19)

1. Agarwal R, Diwanay S, Patki P, Patwardhan B. Studies on immunomodulatory activity of Withania somnifera (Ashwagandha) extract in experimental immune inflammation. J Ethnopharmacol 1999;67:27-35. (Pubitemid 29389740)
2. Xu YM, Marron MT, Seddon E, McLaughlin SP, Ray DT, Whitesell L, Gunatilaka AAL. 2, 3-Dihydrowithaferin A-3beta-O-sulfate, a newpotential prodrug of withaferinAfromaeroponically grown Withania somnifera. Bioorg Med Chem 2009;17(6):2210-2214.
3. Falsey RR, Marron MT, Gunaherath GM, Shirahatti N, Mahadevan D, Gunatilaka AAL, Whitesell L. Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat Chem Biol 2006;2(1):33-38.
4. Yu Y, Hamza A, Zhang T, Gu M, Zou P, Newman B, Li Y, Gunatilaka AAL, Zhan CG, Sun D. Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol 2010;79(4):542-551.
5. Stan SD, Hahm E-R, Warin R, Singh SV. Withaferin A causes FOXO3a-and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res 2008;68:7661.
6. Yang H, Shi G, Dou QP.The tumor proteasome is a primary target for the natural anticancer compound withaferin A isolated from "Indian winter cherry". Mol Pharmacol 2007;71(2):426-437. (Pubitemid 46147909)
7. Bargagna-Mohan P, Hamza A, Kim YE, Ho YK, Mor-Vaknin N, Wendschlag N, Liu JJ, Evans RM, Markovitz DM, Zhan CG, Kim KB, Mohan R.The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol 2007;14:623-634. (Pubitemid 46920982)
8. Kaileh M, Vanden Berghe W, Heyerick A, Horion J, Piette J, Libert C, De Keukeleire D, Essawi T, Haegeman G. Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem 2007;282:4253-4264. (Pubitemid 47100978)
9. Sen N, Banerjee B, Das BB, Ganguly A, Sen T, Pramanik S, Mukhopadhyay S, Majumder HK. Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I-DNA complex. Cell Death Differ 2007;14:358-367. (Pubitemid 46092238)
10. Srinivasan S, Ranga RS, Burikhanov R, Han S-S, Chendil D. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res 2007;67:246-253. (Pubitemid 46142781)
11. Chandana S, Mahadevan D. Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype? Expert Rev Mol Med 2009;11:e34.
12. Wijeratne EMK, Xu Y, Marron MT, Whitesell L, Gunatilaka AAL. Isolation and synthesis of analogues of the anticancer natural product withaferin a for structure-activity relationship studies [Abstracts]. 42nd western regional meeting of the American Chemical Society, Las Vegas, NV, USA, Sept. 2008;23-27.
13. Mahadevan D, Spier C, Della Croce K, Miller S, George B, Riley C, Warner S, Grogan TM, Miller TP. Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol Cancer Ther 2005;4:1867-1879. (Pubitemid 43056970)
14. Sikalidis AK, Lee JI, Stipanuk MH. Gene expression and integrated stress response in HepG2/C3A cells cultured in amino acid deficient medium. Amino Acids 2011;41:159-171.
15. Hackl C, Lang SA, Moser C, Mori A, Fichtner-Feigl S, Hellerbrand C, Dietmeier W, Schlitt HJ, Geissler EK, Stoeltzing O. Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer 2010;10:668.
16. Gozzelino R, Jeney V, Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 2010;50:323-354.
17. Jozkowicz A, Was H, Dulak J. Heme oxygenase-1 in tumors: is it a false friend? Antioxid Redox Signal 2007; 9(12):2099-2117. (Pubitemid 350059009)
18. Lo M, Ling V, Wang YZ, Gout PW. The xc-cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer 2008;99(3):464-472.
19. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823-837.